Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).

Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna.

Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast cancer estimates worldwide.

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz and Dr Erica Kaye to discuss qualitative in oncology.

Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak and Dr Marissa Baker to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA.

Dr Andre Pfob and Prof Peter Dubsky discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.

Deputy Editor Ali Landman speaks with Matthias Preusser about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.

Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, discusses his SunRISe4-trial published in our October issue.

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas.